AZD-5718
- Generic Name
- AZD-5718
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma
- First Posted Date
- 2022-02-22
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 666
- Registration Number
- NCT05251259
- Locations
- π¬π§
Research Site, Watford, United Kingdom
Study to Assess Relative Bioavailability and Safety of AZD5718 in Healthy Volunteers
- First Posted Date
- 2021-02-02
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT04734275
- Locations
- π¬π§
Research Site, London, United Kingdom
PASSIvation of Vulnerable Plaque With AZD5718 in AcuTe Coronary syndromE
- First Posted Date
- 2020-10-23
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- National University Heart Centre, Singapore
- Target Recruit Count
- 243
- Registration Number
- NCT04601467
- Locations
- πΈπ¬
Ng Teng Fong General Hospital (NTFGH), Singapore, Singapore
πΈπ¬Tan Tock Seng Hospital (TTSH), Singapore, Singapore
π³πΏNorth Shore Hospital, Auckland, New Zealand
A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease
Phase 2
Terminated
- Conditions
- Chronic Kidney Disease
- Interventions
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 613
- Registration Number
- NCT04492722
- Locations
- πΊπ¦
Research Site, Zhytomyr, Ukraine
A Study to Assess the Effect of Multiple Doses of AZD5718 on Pharmacokinetics of Oral Midazolam in Healthy Subjects
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT04492709
- Locations
- π¬π§
Research Site, Harrow, United Kingdom
AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD).
- First Posted Date
- 2017-10-23
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 129
- Registration Number
- NCT03317002
- Locations
- πΈπͺ
Research Site, Uppsala, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath